Each study cycle is 28 days. Participant will take ruxolitinib tablets by mouth with a cup of water (about 8 ounces) either 1 or 2 times each day. Participant will continue to receive ruxolitinib at the same dose and schedule that they were assigned in Study 2007-0169. The study staff will remind participant to which schedule they have been assigned.